Segment and Geographic Information (Details) $ in Millions		3 Months Ended								12 Months Ended
		Jun. 27, 2015 USD ($)	Mar. 28, 2015 USD ($)	Dec. 27, 2014 USD ($)	Sep. 27, 2014 USD ($)	Jun. 28, 2014 USD ($)	Mar. 29, 2014 USD ($)	Dec. 28, 2013 USD ($)	Sep. 28, 2013 USD ($)	Jun. 27, 2015 USD ($) segments		Jun. 28, 2014 USD ($) customers		Jun. 29, 2013 USD ($) customers
Segment Reporting Information [Line Items]
Number of Reportable Segments | segments										4
Net sales		$ 1,531.6	$ 1,049.1	$ 1,071.7	$ 951.5	$ 1,144.2	$ 1,004.2	$ 979.0	$ 933.4	$ 4,603.9	[1]	$ 4,060.8	[1]	$ 3,539.8	[1]
Operating income	[1]									$ 747.7		$ 567.0		$ 679.1
Operating income %	[1]									16.20%		14.00%		19.20%
Assets	[1]	19,720.6				13,852.8				$ 19,720.6		$ 13,852.8		$ 5,336.9
Capital expenditures	[1]									137.0		171.6		132.2
Property and equip, net	[1]	932.4				779.9				932.4		779.9		681.4
Depreciation/amortization	[1]									548.8		358.9		160.2
All Countries [Domain]
Segment Reporting Information [Line Items]
Net sales										4,603.9
CHC [Member]
Segment Reporting Information [Line Items]
Net sales										2,750.0		2,849.4		2,671.0
Operating income										$ 405.6		$ 413.1		$ 401.8
Operating income %										14.70%		14.50%		15.00%
Assets		4,381.6				4,931.0				$ 4,381.6		$ 4,931.0		$ 3,447.5
Capital expenditures										80.5		128.3		97.1
Property and equip, net		600.0				577.3				600.0		577.3		508.0
Depreciation/amortization										123.2		106.6		96.1
CHC [Member] | Cough/Cold [Member]
Segment Reporting Information [Line Items]
Net sales	[2]									486.2		510.1		500.6
CHC [Member] | Analgesics [Member]
Segment Reporting Information [Line Items]
Net sales	[2]									441.7		504.0		536.0
CHC [Member] | Gastrointestinal [Member]
Segment Reporting Information [Line Items]
Net sales	[2]									395.3		400.1		388.8
CHC [Member] | Smoking Cessation [Member]
Segment Reporting Information [Line Items]
Net sales										299.4		236.8		193.2
CHC [Member] | Animal Health [Member]
Segment Reporting Information [Line Items]
Net sales										156.9		178.0		123.2
CHC [Member] | Other CHC [Member]
Segment Reporting Information [Line Items]
Net sales	[2]									335.9		468.7		420.9
CHC [Member] | Infant Nutritionals [Member]
Segment Reporting Information [Line Items]
Net sales										383.9		374.8		350.1
CHC [Member] | Vitamins, Minerals, and Dietary Supplements [Member]
Segment Reporting Information [Line Items]
Net sales										185.6		176.9		158.3
CHC [Member] | CHC [Member]
Segment Reporting Information [Line Items]
Net sales										2,684.9		2,849.4		2,671.1
BCH [Member]
Segment Reporting Information [Line Items]
Net sales	[3]									401.1		0.0		0.0
Operating income	[3]									$ 26.6		$ 0.0		$ 0.0
Operating income %	[3]									6.60%		0.00%		0.00%
Assets	[3]	6,441.1				0.0				$ 6,441.1		$ 0.0		$ 0.0
Capital expenditures	[3]									3.6		0.0		0.0
Property and equip, net	[3]	122.5				0.0				122.5		0.0		0.0
Depreciation/amortization	[3]									38.3		0.0		0.0
BCH [Member] | BCH [Member]
Segment Reporting Information [Line Items]
Net sales										401.2		0.0		0.0
Rx Pharmaceuticals [Member]
Segment Reporting Information [Line Items]
Net sales										1,001.1		927.1		709.5
Operating income										$ 373.9		$ 349.8		$ 263.2
Operating income %										37.30%		37.70%		37.10%
Assets		2,667.9				2,537.2				$ 2,667.9		$ 2,537.2		$ 1,604.9
Capital expenditures										42.9		32.9		17.7
Property and equip, net		124.1				104.8				124.1		104.8		80.8
Depreciation/amortization										85.1		86.5		54.9
Rx Pharmaceuticals [Member] | Rx Pharmaceuticals [Member]
Segment Reporting Information [Line Items]
Net sales										1,066.1		927.1		709.5
Specialty Sciences [Member]
Segment Reporting Information [Line Items]
Net sales										344.0	[4]	$ 146.7		0.0	[4]
Operating income	[4]									$ 36.3				$ 0.0
Operating income %	[4]									10.60%		(47.00%)		0.00%
Assets	[4]	5,979.0				6,096.6				$ 5,979.0		$ 6,096.6		$ 0.0
Capital expenditures	[4]									0.5				0.0
Property and equip, net	[4]	0.0				2.1				0.0		2.1		0.0
Depreciation/amortization	[4]									291.6				0.0
All Other Segments [Member]
Segment Reporting Information [Line Items]
Net sales										107.7		137.6		159.3
Operating income										$ 26.8		$ 46.1		$ 48.9
Operating income %										24.90%		33.50%		30.70%
Assets		251.0				288.0				$ 251.0		$ 288.0		$ 284.5
Capital expenditures										6.4		10.4		17.3
Property and equip, net		85.8				95.7				85.8		95.7		92.7
Depreciation/amortization										10.6		11.4		9.1
Significant Reconciling Items [Member]
Segment Reporting Information [Line Items]
Net sales										0.0		0.0		0.0
Operating income										$ (121.5)		$ (173.4)		$ (34.7)
Operating income %										0.00%		0.00%		0.00%
Assets		0.0				0.0				$ 0.0		$ 0.0		$ 0.0
Capital expenditures										3.1		0.0		0.0
Property and equip, net		0.0				0.0				0.0		0.0		0.0
Depreciation/amortization										$ 0.0		$ 0.0		$ 0.0
Net Sales [Member] | Customer Concentration Risk [Member]
Segment Reporting Information [Line Items]
Segment Reporting, Number of Major Customers | customers												1		1
Concentration risk percentage										15.00%		19.00%		19.00%
Net Sales [Member] | Customer Concentration Risk [Member] | CHC [Member]
Segment Reporting Information [Line Items]
Segment Reporting, Number of Major Customers | customers												1		1
IRELAND
Segment Reporting Information [Line Items]
Net sales										$ 344.0		$ 146.7		$ 0.0
Property and equip, net		1.4				2.0				1.4		2.0
UNITED STATES
Segment Reporting Information [Line Items]
Net sales										3,303.6		3,291.6		2,978.1
Property and equip, net		558.6				530.7				558.6		530.7
Europe [Member]
Segment Reporting Information [Line Items]
Net sales										613.6		217.2		164.0
Property and equip, net		153.8				31.7				153.8		31.7
ISRAEL [Member]
Segment Reporting Information [Line Items]
Property and equip, net		119.8				119.6				119.8		119.6
Outside United States [Member]
Segment Reporting Information [Line Items]
Net sales	[5]									342.7		405.3		$ 397.7
Property and equip, net		$ 98.8				$ 95.9				$ 98.8		$ 95.9

[1] Amounts may not cross-foot due to rounding.

[2] Includes sales from our OTC contract manufacturing business.

[3] (1) BCH only includes activity from March 30, 2015 to June 27, 2015.

[4] Specialty Sciences only includes activity from December 18, 2013 to June 28, 2014

[5] (2) Includes sales generated primarily in Israel, Mexico, Australia, and Canada.